Molecular dissection of 17q12 amplicon in upper gastrointestinal adenocarcinomas

Molecular Cancer Research

Volumn 4, Issue 7, 2006, Pages 449-455

  Maqani, Nazif ^a   Belkhiri, Abbes ^a   Moskaluk, Christopher ^b   Knuutila, Sakari ^c   Dar, Altaf A ^a   El Rifai, Wael ^a  

^a VANDERBILT INGRAM CANCER CENTER   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; NEUROGENIC DIFFERENTIATION FACTOR;

ARTICLE; C17ORF37 GENE; CONTROLLED STUDY; DARPP 32 GENE; FLUORESCENCE IN SITU HYBRIDIZATION; GASTROINTESTINAL CARCINOMA; GENE; GENE AMPLIFICATION; GENE EXPRESSION; GENE LOCATION; GRB7 GENE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; PERLD1 GENE; PNMT GENE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; STARD3 GENE; TCAP GENE; TISSUE MICROARRAY; TOP2A GENE; ZNFN1A3 GENE;

ADENOCARCINOMA; CHROMOSOMES, HUMAN, PAIR 17; ESOPHAGEAL NEOPLASMS; FEMALE; GENE AMPLIFICATION; GENE DOSAGE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; NEOPLASM STAGING; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; STOMACH NEOPLASMS;

EID: 33746863318     PISSN: 15417786     EISSN: None     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-06-0058     Document Type: Article

References (49)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001;94:153-6.
2. Roder DM. The epidemiology of gastric cancer. Gastric Cancer 2002;5 Suppl 1:5-11.
3. Hohenberger P, Gretschel S. Gastric cancer. Lancet 2003;362:305-15.
4. El-Rifai W, Powell S. Molecular and biologic basis of upper gastrointestinal malignancy gastric carcinoma. Surg Oncol Clin North Am 2002;11: 273-91.
5. el-Serag HB. The epidemic of esophageal adenocarcinoma. Gastroenterol Clin North Am 2002;31:421-40, viii.
6. Todd JA, Johnston DA, Dillon JF. The changing spectrum of gastroesophageal reflux disease. Eur J Cancer Prev 2002;11:215-9.
7. van Soest EM, Dieleman JP, Siersema PD, Sturkenboom MC, Kuipers F.J. Increasing incidence of Barrett's oesophagus in the general population. Gut 2005; 54:1062-6.
8. Varis A, Wolf M, Monni O, et al. Targets of gene amplification and overcxpression at 17q in gastric cancer. Cancer Res 2002;62:2625-9.
9. Moog-Lutz C, Tomasetto C, Regnier CH, et al. MLN64 exhibits homology with the steroidogenic acute regulatory protein (STAR) and is over-expressed in human breast carcinomas. Int J Cancer 1997;71:183-91.
10. Bieche I, Tomasetto C, Regnier CH, Moog-Lutz C, Rio MC, Lidereau R. Two distinct amplified regions at 17q11-q21 involved in human primary breast cancer. Cancer Res 1996;56:3886-90.
11. Bown N, Lastowska M, Cotterill S, et al. 3 7q Gain in neuroblastoma predicts adverse clinical outcome. U.K. Cancer Cytogenetics Group and the U.K. Children's Cancer Study Group. Med Pediatr Oncol 2001;36:14-9.
12. Mahlamaki EH, Barlund M, Tanner M, et al. Frequent amplification of 8q24, 11 q, 17q, and 20q-specific genes in pancreatic cancer. Genes Chromosomes Cancer 2002;35:353-8.
13. Forozan F, Mahlamaki EH, Monni O, et al. Comparative genomic hybridization analysis of 38 breast cancer cell lines: a basis for interpreting complementary DNA microarray data. Cancer Res 2000;60:4519-25.
14. El-Rifai W, Frierson HJ, Moskaluk C, et al. Genetic Differences between adenocarcinomas arising in Barrett's esophagus and gastric mucosa. Gastroenterology 2001;121:592-8.
15. Kokkola A, Monni O, Puolakkainen P, et al. 17q12-21 amplicon, a novel recurrent genetic change in intestinal type of gastric carcinoma: a comparative genomic hybridization study. Genes Chromosomes Cancer 1997;20:38-43.
16. Kauraniemi P, Kuukasjarvi T, Sauter G, Kallioniemi A. Amplification of a 280-kilobase core region at the ERBB2 locus leads to activation of two hypothetical proteins in breast cancer. Am J Pathol 2003;163:1979-84.
17. El-Rifai W, Moskaluk CA, Abdrabbo M, et al. Gastric cancers overexpress S100A calcium binding proteins. Cancer Res 2002;62:6823-6.
18. Bofin AM, Ytterhus B, Hagmar BM. TOP2A and HER-2 gene amplification in fine needle aspirates from breast carcinomas, Cytopathology 2003; 14:314-9.
19. Hicks DG, Yoder BJ, Pettay J, et al. The incidence of topoisomerase II-α genomic alterations in adenocarcinoma of the breast and their relationship to human epidermal growth factor receptor-2 gene amplification: a fluorescence in situ hybridization study. Hum Pathol 2005;36:348-56.
20. Jarvinen TA, Liu ET. HER-2/neu and topoisomerase IIα-simultaneous drug targets in cancer. Comb Chem High Throughput Screen 2003;6:455-70.
21. Simon R, Atefy R, Wagner U, et al. HER-2 and TOP2A coamplification in urinary bladder cancer. Int J Cancer 2003;107:764-72.
22. Baselga J. Herceptin alone or in combination with chemotherapy in the treatment of HER2-positive metastatic breast cancer: pivotal trials. Oncology 2001;61 Suppl 2:14-21.
23. Ahluwalia MS, Daw HA. Neoadjuvant therapy with trastuzumab, paclitaxel and epirubicin for HER-2-positive operable breast cancer. J Clin Oncol 2005;23: 7759-60; author reply 7760-1.
24. Venturini M, Bighin C, Monfardini S, et al. Multicenter phase II study of trastuzumab in combination with epirubicin and docetaxel as first-line treatment for HER2-overexpressing metastatic breast cancer. Breast Cancer Res Treat 2006; 95:45-53.
25. Yano T, Doi T, Ohtsu A, et al. Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer. Oncol Rep 2006;15:65-71.
26. Carneiro F, Sobrinho-Simoes M. The prognostic significance of amplification and overexpression of c-met and c-erbB-2 in human gastric carcinomas, Cancer 2000;88:238-40.
27. Ross JS, McKenna BJ. The HER-2/neu oncogene in tumors of the gastrointestinal tract. Cancer Invest 2001;19:554-68.
28. Takehana T, Kunitomo K, Kono K, et al. Status of c-erbB-2 in gastric adenocarcinoma: a comparative study of immunohistochemistry, fluorescence in situ hybridization and enzyme-linked immuno-sorbent assay. Int J Cancer 2002;98:833-7.
29. Katoh M, Katoh M. Evolutionary recombination hotspot around GSDML-GSDM locus is closely linked to the oncogenomic recombination hotspot around the PPPIR1B-ERBB2-GRB7 amplicon. Int J Oncol 2004;24:757-63.
30. Pera M, Manterola C, Vidal O, Grande L. Epidemiology of esophageal adenocarcinoma. J Surg Oncol 2005;92:151-9.
31. Ronkainen J, Aro P, Storskrubb T, et al. Prevalence of Barrett's esophagus in the general population: an endoscopic study. Gastroenterology 2005;129: 1825-31.
32. Kauraniemi P, Bärlund M, Monni O, Kallioniemi A. New amplified and highly expressed genes discovered in the ERBB2 amplicon in breast cancer by cDNA microarrays. Cancer Res 2001;61:8235-40.
33. El-Rifai W, Smith MF, Jr., Li G, et al. Gastric cancers overexpress DARPP-32 and a novel isoform, t-DARPP. Cancer Res 2002;62:4061-4.
34. Beckler A, Moskaluk CA, Zaika A, et al. Overexpression of the 32-kilodalton dopamine and cyclic adenosine 3′,5′-monophosphate- regulated phosphoprotein in common adenocarcinomas. Cancer 2003;98:1547-51.
35. Ebihara Y, Miyamoto M, Fukunaga A, et al. DARPP-32 expression arises after a phase of dysplasia in oesophageal squamous cell carcinoma. Br J Cancer 2004;91:119-23.
36. Wang MS, Pan Y, Liu N, Guo C, Hong L, Fan D. Overexpression of DARPP-32 in colorectal adenocarcinoma. Int J Clin Pract 2005;59:58-61.
37. Belkhiri A, Zaika A, Pidkovka N, Knuutila S, Moskaluk C, El-Rifai W. Darpp-32: a novel antiapoptotic gene in upper gastrointestinal carcinomas. Cancer Res 2005;65:6583-92.
38. Walch A, Bink K, Gais P, et al. Evaluation of c-erbB-2 Overexpression and HER-2/neu gene copy number heterogeneity in Barrett's adenocarcinoma. Anal Cell Pathol 2000;20:25-32.
39. Walch A, Specht K, Braselmann H, et al. Coamplification and coexpression of GRB7 and ERBB2 is found in high grade intraepithelial neoplasia and in invasive Barrett's carcinoma. Int J Cancer 2004;112:747-53.
40. Vinatzer U, Dampier B, Streubel B, et al. Expression of HER2 and the coamplified genes GRB7 and MLN64 in human breast cancer: quantitative real-time reverse transcription-PCR as a diagnostic alternative to immunohistochemistry and fluorescence in situ hybridization. Clin Cancer Res 2005;11: 8348-57.
41. Dursun A, Poyraz A, Celik B, Akyol G. Expression of c-erbB-2 oncoprotein in gastric carcinoma: correlation with histopathologic characteristics and analysis of Ki-67. Pathol Oncol Res 1999;5:104-6.
42. Risio M, De Rosa G, Sarotto I, et al. HER2 testing in gastric cancer: molecular morphology and storage time-related changes in archival samples. Int J Oncol 2003;23:1381-7.
43. Vans A, Zaika A, Puolakkainen P, et al. Coamplified and overexpressed genes at ERBB2 locus in gastric cancer. Int J Cancer 2004;109:548-53.
44. Keith WN, Tan KB, Brown R. Amplification of the topoisomerase IIα gene in a non-small cell lung cancer cell line and characterisation of polymorphisms at the human topoisomerase II α and β loci in normal tissue. Genes Chromosomes Cancer 1992;4:169-75.
45. Harris LN, Yang L, Liotcheva V, et al. Induction of topoisomerase II activity after ErbB2 activation is associated with a differential response to breast cancer chemotherapy. Clin Cancer Res 2001;7:1497-504.
46. Jarvinen TA, Liu ET. HER-2/neu and topoisomerase IIa in breast cancer. Breast Cancer Res Treat 2003;78:299-311.
47. Ross JS, Fletcher JA, Bloom KJ, et al. Targeted therapy in breast cancer: the HER-2/neu gene and protein. Mol Cell Proteomics 2004;3:379-98.
48. Jarvinen TA, Holli K, Kuukasjarvi T, Isola JJ. Predictive value of topoisomerase IIα and other prognostic factors for epirubicin chemotherapy in advanced breast cancer. Br J Cancer 1998;77:2267-73.
49. Kent WJ, Sugnet CW, Furey TS, et al. The Human Genome Browser at UCSC Genome Res 2002;12:996-1006.